Literature DB >> 24367931

Long-term effect on natural killer cells by interferon-α therapy on the outcomes of HCV infection.

Xiaoli Hu1, Yanfang Jiang, Xiurong Li, Yanhang Gao, Xiaoli Guo, Xiumei Chi, Hongqing Yan, Junyan Feng, Jin Zhong, Bing Sun, Xue Shao, Weihua Xiao, Yu Pan, Junqi Niu.   

Abstract

Natural killer (NK) cells act as innate immune cells against hepatitis C virus (HCV) infection. Interferon-α (IFN-α) and ribavirin are the standard treatments for patients with HCV infection. This study is aimed at investigating the dynamic changes in the frequency of different subsets of NK cells following treatment in xx chronic hepatitis C (CHC) patients. CHC patients were treated with peg-IFN or IFN-α, and followed up for 72 weeks. The frequency of different subsets of NK in CHC patients was determined longitudinally by flow cytometry. Treatment with the standard therapy increased the percentages of NKp30(+), NKp46(+), and CD107a(+) NK cells, which were positively correlated with the declining of serum HCV-RNA, but not IFN-γ(+) NK cells. NKG2A(+) and KIR2DL3(+) NK cells were associated with an early virological response in CHC patients. Treatment with IFN-α adjusts the balance of activated receptors and inhibitory receptors and enhances the cytotoxic activity of NK cells. Therefore, measuring NK subsets may be valuable for therapeutic responses in CHC patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24367931      PMCID: PMC4015508          DOI: 10.1089/jir.2013.0049

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  40 in total

Review 1.  Activation of NK cell cytotoxicity.

Authors:  Mark J Smyth; Erika Cretney; Janice M Kelly; Jennifer A Westwood; Shayna E A Street; Hideo Yagita; Kazuyoshi Takeda; Serani L H van Dommelen; Mariapia A Degli-Esposti; Yoshihiro Hayakawa
Journal:  Mol Immunol       Date:  2005-02       Impact factor: 4.407

2.  Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.

Authors:  J Nattermann; G Feldmann; G Ahlenstiel; B Langhans; T Sauerbruch; U Spengler
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

3.  Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes.

Authors:  S Norris; C Collins; D G Doherty; F Smith; G McEntee; O Traynor; N Nolan; J Hegarty; C O'Farrelly
Journal:  J Hepatol       Date:  1998-01       Impact factor: 25.083

4.  Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation.

Authors:  Zlatko Trobonjaca; Andrea Kröger; Detlef Stober; Frank Leithäuser; Peter Möller; Hansjörg Hauser; Reinhold Schirmbeck; Jörg Reimann
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

5.  Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.

Authors:  M A Cooper; T A Fehniger; S C Turner; K S Chen; B A Ghaheri; T Ghayur; W E Carson; M A Caligiuri
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

6.  Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.

Authors:  Birgit Edlich; Golo Ahlenstiel; Aintzane Zabaleta Azpiroz; Jonathan Stoltzfus; Mazen Noureddin; Elisavet Serti; Jordan J Feld; T Jake Liang; Yaron Rotman; Barbara Rehermann
Journal:  Hepatology       Date:  2011-11-14       Impact factor: 17.425

7.  HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection.

Authors:  Salim I Khakoo; Chloe L Thio; Maureen P Martin; Collin R Brooks; Xiaojiang Gao; Jacquie Astemborski; Jie Cheng; James J Goedert; David Vlahov; Margaret Hilgartner; Steven Cox; Ann-Margeret Little; Graeme J Alexander; Matthew E Cramp; Stephen J O'Brien; William M C Rosenberg; David L Thomas; Mary Carrington
Journal:  Science       Date:  2004-08-06       Impact factor: 47.728

8.  CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.

Authors:  A W Lin; S A Gonzalez; S Cunningham-Rundles; G Dorante; S Marshall; A Tignor; C Ha; I M Jacobson; A H Talal
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

9.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

10.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.

Authors:  Claire Dunn; Maurizia Brunetto; Gary Reynolds; Theodoros Christophides; Patrick T Kennedy; Pietro Lampertico; Abhishek Das; A Ross Lopes; Persephone Borrow; Kevin Williams; Elizabeth Humphreys; Simon Afford; David H Adams; Antonio Bertoletti; Mala K Maini
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

View more
  5 in total

1.  Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases.

Authors:  Valli De Re; Laura Caggiari; Mariangela De Zorzi; Ombretta Repetto; Anna Linda Zignego; Francesco Izzo; Maria Lina Tornesello; Franco Maria Buonaguro; Alessandra Mangia; Domenico Sansonno; Vito Racanelli; Salvatore De Vita; Pietro Pioltelli; Emanuela Vaccher; Massimiliano Berretta; Massimiliano Beretta; Cesare Mazzaro; Massimo Libra; Andrea Gini; Antonella Zucchetto; Renato Cannizzaro; Paolo De Paoli
Journal:  PLoS One       Date:  2015-02-20       Impact factor: 3.240

2.  The evolving role of interferons in viral eradication strategies.

Authors:  Tomas Doyle
Journal:  J Virus Erad       Date:  2016-04-01

Review 3.  The viral innate immune antagonism and an alternative vaccine design for PRRS virus.

Authors:  Hanzhong Ke; Dongwan Yoo
Journal:  Vet Microbiol       Date:  2017-03-18       Impact factor: 3.293

4.  NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B.

Authors:  Xiaokun Shen; Binqing Fu; Yanyan Liu; Chuang Guo; Ying Ye; Rui Sun; Jiabin Li; Zhigang Tian; Haiming Wei
Journal:  Sci Rep       Date:  2016-12-12       Impact factor: 4.379

Review 5.  Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection.

Authors:  Gaitan Fabrice Njiomegnie; Scott A Read; Nicole Fewings; Jacob George; Fiona McKay; Golo Ahlenstiel
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.